Suppr超能文献

广义风险调整成本效益评估(GRACE)的扩展和实施指南。

A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE).

机构信息

School of Pharmacy, Sol Price School of Public Policy, The Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles, CA, USA.

The National Bureau of Economic Research (NBER), Cambridge, MA, USA.

出版信息

Eur J Health Econ. 2022 Apr;23(3):433-451. doi: 10.1007/s10198-021-01367-0. Epub 2021 Sep 8.

Abstract

The generalized risk-adjusted cost-effectiveness (GRACE) model generalizes conventional cost-effectiveness analysis (CEA) by introducing diminishing returns to Health-Related Quality of Life (QoL). This changes CEA practice in three ways: (1) Willingness to pay (WTP) increases exponentially with untreated illness severity or pre-existing permanent disability, and WTP ends up lower for mild diseases but higher for severe diseases compared with conventional CEA; (2) Average treatment effectiveness should be adjusted for uncertainty in outcomes; and (3) The marginal rate of substitution between life expectancy and QoL varies with health state. Implementing GRACE requires new parameters describing risk preferences over QoL, the marginal rate of substitution between life expectancy (LE) and QoL, and the variance and skewness of treatment outcomes distributions. In this paper, we provide: (1) a generalized WTP threshold incorporating the possibility of permanent disability; (2) a simpler method to estimate the tradeoff rate between QoL and LE, eliminating the need to carry out treatment-by-treatment estimates; (3) a more-general method to adjust WTP for illness severity that permits non-constant relative risk-aversion in QoL; (4) a new approach to estimating risk-preferences over QoL, leveraging established empirical methods from "happiness" economics; and (5) a step-by-step guide for practitioners wishing to implement multi-period GRACE analyses.

摘要

广义风险调整成本效益(GRACE)模型通过引入健康相关生活质量(QoL)的收益递减来推广传统的成本效益分析(CEA)。这在以下三个方面改变了 CEA 实践:(1)未治疗疾病严重程度或预先存在的永久性残疾的意愿支付(WTP)呈指数增长,与传统 CEA 相比,轻度疾病的 WTP 较低,但严重疾病的 WTP 较高;(2)应根据结果的不确定性调整平均治疗效果;(3)预期寿命和 QoL 之间的边际替代率随健康状况而变化。实施 GRACE 需要新的参数来描述对 QoL 的风险偏好、预期寿命(LE)和 QoL 之间的边际替代率,以及治疗结果分布的方差和偏度。在本文中,我们提供了:(1)包含永久性残疾可能性的广义 WTP 阈值;(2)一种更简单的方法来估计 QoL 和 LE 之间的权衡率,消除了逐个治疗进行估计的需要;(3)一种更通用的方法来调整 WTP 以适应疾病严重程度,允许 QoL 中的非恒定相对风险厌恶;(4)一种新的方法来估计 QoL 的风险偏好,利用“幸福”经济学中已建立的实证方法;(5)希望实施多期 GRACE 分析的从业者的分步指南。

相似文献

3
Health technology assessment with risk aversion in health.健康风险厌恶的卫生技术评估。
J Health Econ. 2020 Jul;72:102346. doi: 10.1016/j.jhealeco.2020.102346. Epub 2020 Jun 6.
10

引用本文的文献

1
Measuring the Budget Impact of Nondiscriminatory Cost-Effectiveness.衡量非歧视性成本效益的预算影响。
JAMA Health Forum. 2025 Sep 5;6(9):e253076. doi: 10.1001/jamahealthforum.2025.3076.
3
Health Risk and the Value of Life.健康风险与生命价值。
J Public Econ. 2025 May;245. doi: 10.1016/j.jpubeco.2025.105346. Epub 2025 Apr 3.
9
A principled approach to non-discrimination in cost-effectiveness.基于原则的成本效益非歧视方法。
Eur J Health Econ. 2024 Nov;25(8):1393-1416. doi: 10.1007/s10198-023-01659-7. Epub 2024 Feb 27.
10
Incorporating Real Option Value in Valuing Innovation: A Way Forward.将实物期权价值纳入创新估值:一种前进的方式。
Pharmacoeconomics. 2024 Jul;42(Suppl 2):199-210. doi: 10.1007/s40273-024-01352-4. Epub 2024 Feb 4.

本文引用的文献

4
Health technology assessment with risk aversion in health.健康风险厌恶的卫生技术评估。
J Health Econ. 2020 Jul;72:102346. doi: 10.1016/j.jhealeco.2020.102346. Epub 2020 Jun 6.
7
An elicitation of utility for quality of life under prospect theory.前景理论下生活质量效用的引出
J Health Econ. 2016 Jul;48:121-34. doi: 10.1016/j.jhealeco.2016.04.002. Epub 2016 May 2.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验